Floatz logo

Anti-Trbc1 Car-T Cell Therapy

Acute T Cell Leukemia

Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineCell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

80 Active assets in the Acute T Cell Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Children's Oncology Group
Phase 3BB
PEGASPARGASE
Children's Oncology Group
Phase 3BB
MERCAPTOPURINE ANHYDROUS
SWOG Cancer Research Network
Phase 3BB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
University of Washington
Phase 3BB
Daunorubicin
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

Anti-Trbc1 Car-T Cell Therapy is also rated in:

anaplastic large cell lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
angioimmunoblastic T-cell lymphomaDormant
CC
Indicative ·
41 / 100
View asset →
T-lymphoblastic lymphomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →